Cyted Health

Cyted Health is a commercial-stage diagnostics company focused on revolutionizing the early detection of gastrointestinal diseases, particularly esophageal cancer and its precursor, Barrett's Esophagus. Its core technology is the EndoSign® capsule sponge, a minimally invasive device for cell collection, which is integrated with advanced molecular diagnostics. The company has achieved significant milestones including FDA 510(k) clearance, initiation of a major UK screening trial (BEST4), and a $44 million Series B financing round to accelerate US expansion.

Non-endoscopic diagnostic platform centered on the EndoSign® capsule sponge device for esophageal cell collection, integrated with advanced molecular biomarker analysis and data analytics.

Cyted competes with traditional invasive endoscopy, which is the standard of care but has scalability limitations. Emerging competitors include other non-endoscopic cell collection devices, swallowable imaging capsules, and liquid biopsy tests for cancer detection. Cyted's first-mover advantage with an FDA-cleared device is a key differentiator.